Fate Therapeutics announces completion of public offering of common stock
Fate Therapeutics announced the closing of an underwritten public offering of 10,953,750 shares of its common stock, which included 1,428,750 shares that were issued pursuant to the full exercise of the underwriters' option. Net proceeds were $42.9 million. December 15, 2017